Home » Stocks » Xencor

Xencor, Inc. (XNCR)

Stock Price: $39.48 USD -0.01 (-0.03%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $39.47 -0.01 (-0.02%) Oct 23, 4:12 PM

Stock Price Chart

Key Info

Market Cap 2.26B
Revenue (ttm) 70.75M
Net Income (ttm) -80.23M
Shares Out 57.24M
EPS (ttm) -1.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $39.48
Previous Close $39.49
Change ($) -0.01
Change (%) -0.03%
Day's Open 39.92
Day's Range 38.99 - 40.44
Day's Volume 180,662
52-Week Range 19.35 - 43.90

More Stats

Market Cap 2.26B
Enterprise Value 1.68B
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 57.24M
Float 56.91M
EPS (basic) -1.40
EPS (diluted) -1.41
FCF / Share -0.92
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.84M
Short Ratio 8.99
Short % of Float 6.75%
Beta 0.79
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 31.94
PB Ratio 3.91
Revenue 70.75M
Operating Income -91.23M
Net Income -80.23M
Free Cash Flow -52.46M
Net Cash 576.54M
Net Cash / Share 10.07
Gross Margin 53.87%
Operating Margin -128.94%
Profit Margin -113.40%
FCF Margin -74.14%
ROA -8.56%
ROE -13.61%
ROIC -15.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (12)

Buy 10
Overweight 0
Hold 1
Underweight 0
Sell 1

Analyst Consensus: Buy

Price Target

$45.45*
(15.12% upside)
Low
28.0
Current: $39.48
High
56.0
Target: 45.45
*Average 12-month price target from 11 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue15740.6046.1510927.769.5210.179.526.85
Revenue Growth285.93%-12.02%-57.67%292.7%191.62%-6.41%6.8%39.06%-
Gross Profit15740.6046.1510927.769.5210.179.526.85
Operating Income13.82-79.37-43.1244.04-18.34-16.46-10.52-6.23-9.45
Net Income26.88-70.41-38.4945.13-17.59-16.42-60.26-8.59-11.20
Shares Outstanding56.5353.9446.8241.2739.0231.392.470.070.07
Earnings Per Share0.46-1.31-0.821.07-0.45-0.52-3.85-118.86-154.95
Operating Cash Flow64.37-79.76-33.6095.2426.67-21.35-5.45-11.05-1.09
Capital Expenditures-7.35-7.20-5.31-1.51-1.92-0.78-0.120.060.08
Free Cash Flow57.02-86.96-38.9193.7324.75-22.13-5.57-11.00-1.01
Cash & Equivalents53029422413096.4354.6577.982.31-
Total Debt10.73-----0.0120.94-
Net Cash / Debt51929422413096.4354.6577.97-18.63-
Assets67057739042920767.8287.3211.66-
Liabilities77.0555.0573.7411544.488.5313.7831.16-
Book Value59352231631416259.2973.53-166-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Xencor, Inc.
Country United States
Employees 166
CEO Bassil I. Dahiyat

Stock Information

Ticker Symbol XNCR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: XNCR
IPO Date December 3, 2013

Description

Xencor, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat cancer and autoimmune diseases. The company's product candidates include XmAb5871, an immune inhibitor, which has been completed Phase II clinical trial for the treatment of autoimmune diseases; AIMab7195, which is in development and commercialization stage. Its product candidates also comprise XmAb14045, a bispecific antibody which is in Phase I clinical trial for the treatment of acute myeloid leukemia; plamotamab (XmAb13676) that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers Tafasitamab, an antibody drug candidate for the treatment of patients with relapsed/refractory diffuse; AMG424, a bispecific antibody that targets CD38 and CD3, which is in Phase I clinical trial for the treatment of various myeloma; and AMG509, a bispecific antibody that is in preclinical development stage to treat prostate cancer. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, and XmAb23104 which are in preclinical Phase. Additionally, it offers XmAb24306, initial cytokine candidate which is in Phase I clinical trial. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc.; MorphoSys Ag; Amgen Inc.; and Catalent Pharma Solutions LLC. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.